Pub Date : 2022-11-01Epub Date: 2022-10-07DOI: 10.1016/S2213-2600(22)00405-2
Talha Burki
{"title":"The upcoming influenza season and protection from vaccines.","authors":"Talha Burki","doi":"10.1016/S2213-2600(22)00405-2","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00405-2","url":null,"abstract":"","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"1018"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33499361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01Epub Date: 2022-08-18DOI: 10.1016/S2213-2600(22)00226-0
Seran Hakki, Jie Zhou, Jakob Jonnerby, Anika Singanayagam, Jack L Barnett, Kieran J Madon, Aleksandra Koycheva, Christine Kelly, Hamish Houston, Sean Nevin, Joe Fenn, Rhia Kundu, Michael A Crone, Timesh D Pillay, Shazaad Ahmad, Nieves Derqui-Fernandez, Emily Conibear, Paul S Freemont, Graham P Taylor, Neil Ferguson, Maria Zambon, Wendy S Barclay, Jake Dunning, Ajit Lalvani
<p><strong>Background: </strong>Knowledge of the window of SARS-CoV-2 infectiousness is crucial in developing policies to curb transmission. Mathematical modelling based on scarce empirical evidence and key assumptions has driven isolation and testing policy, but real-world data are needed. We aimed to characterise infectiousness across the full course of infection in a real-world community setting.</p><p><strong>Methods: </strong>The Assessment of Transmission and Contagiousness of COVID-19 in Contacts (ATACCC) study was a UK prospective, longitudinal, community cohort of contacts of newly diagnosed, PCR-confirmed SARS-CoV-2 index cases. Household and non-household exposed contacts aged 5 years or older were eligible for recruitment if they could provide informed consent and agree to self-swabbing of the upper respiratory tract. The primary objective was to define the window of SARS-CoV-2 infectiousness and its temporal correlation with symptom onset. We quantified viral RNA load by RT-PCR and infectious viral shedding by enumerating cultivable virus daily across the course of infection. Participants completed a daily diary to track the emergence of symptoms. Outcomes were assessed with empirical data and a phenomenological Bayesian hierarchical model.</p><p><strong>Findings: </strong>Between Sept 13, 2020, and March 31, 2021, we enrolled 393 contacts from 327 households (the SARS-CoV-2 pre-alpha and alpha variant waves); and between May 24, 2021, and Oct 28, 2021, we enrolled 345 contacts from 215 households (the delta variant wave). 173 of these 738 contacts were PCR positive for more than one timepoint, 57 of which were at the start of infection and comprised the final study population. The onset and end of infectious viral shedding were captured in 42 cases and the median duration of infectiousness was 5 (IQR 3-7) days. Although 24 (63%) of 38 cases had PCR-detectable virus before symptom onset, only seven (20%) of 35 shed infectious virus presymptomatically. Symptom onset was a median of 3 days before both peak viral RNA and peak infectious viral load (viral RNA IQR 3-5 days, n=38; plaque-forming units IQR 3-6 days, n=35). Notably, 22 (65%) of 34 cases and eight (24%) of 34 cases continued to shed infectious virus 5 days and 7 days post-symptom onset, respectively (survival probabilities 67% and 35%). Correlation of lateral flow device (LFD) results with infectious viral shedding was poor during the viral growth phase (sensitivity 67% [95% CI 59-75]), but high during the decline phase (92% [86-96]). Infectious virus kinetic modelling suggested that the initial rate of viral replication determines the course of infection and infectiousness.</p><p><strong>Interpretation: </strong>Less than a quarter of COVID-19 cases shed infectious virus before symptom onset; under a crude 5-day self-isolation period from symptom onset, two-thirds of cases released into the community would still be infectious, but with reduced infectious viral shedding. Our
背景:了解SARS-CoV-2的传染窗口期对于制定遏制传播的政策至关重要。基于稀缺经验证据和关键假设的数学建模推动了隔离和检测政策，但需要真实世界的数据。我们的目标是在现实世界的社区环境中描述整个感染过程的传染性。方法:“接触者中COVID-19传播和传染性评估”(ATACCC)研究是一项英国前瞻性、纵向、社区队列研究，研究对象是新诊断、pcr确诊的SARS-CoV-2指数病例的接触者。年龄在5岁或以上的家庭和非家庭接触者如果能够提供知情同意并同意自行擦拭上呼吸道，则符合招募资格。主要目的是确定SARS-CoV-2传染性窗口期及其与症状发作的时间相关性。我们通过RT-PCR定量病毒RNA载量，并通过在感染过程中每天计数可培养病毒来定量感染性病毒脱落。参与者完成了一份每日日记，以跟踪症状的出现。结果评估与经验数据和现象学贝叶斯层次模型。研究结果:在2020年9月13日至2021年3月31日期间，我们招募了来自327个家庭的393名接触者(SARS-CoV-2前α和α变异波);在2021年5月24日至2021年10月28日期间，我们招募了来自215个家庭的345名联系人(δ变体波)。这738名接触者中有173人在一个以上时间点呈PCR阳性，其中57人在感染开始时即构成最终研究人群。42例捕捉到感染性病毒脱落的开始和结束，中位感染持续时间为5 (IQR 3-7)天。虽然38例患者中有24例(63%)在症状出现前有pcr检测到的病毒，但35例患者中只有7例(20%)在症状前有传染性病毒。症状出现的中位数为病毒RNA峰值和感染病毒载量峰值前3天(病毒RNA IQR 3-5天，n=38;斑块形成单位IQR 3-6天，n=35)。值得注意的是，34例患者中有22例(65%)和34例患者中有8例(24%)在症状出现后5天和7天继续传播传染性病毒(生存率分别为67%和35%)。侧流装置(LFD)结果与感染性病毒脱落的相关性在病毒生长期较差(敏感性67% [95% CI 59-75])，但在下降期较高(92%[86-96])。感染病毒动力学模型表明，病毒复制的初始速率决定了感染过程和传染性。解释:不到四分之一的COVID-19病例在出现症状之前就已经传播了传染性病毒;在症状出现后粗略的5天自我隔离期内，三分之二进入社区的病例仍具有传染性，但传染性病毒的释放减少了。我们的研究结果支持lfd在安全加速去隔离方面的作用，但除非每天使用，否则不能用于早期诊断。这些基于社区的高分辨率数据为感染控制指导提供了证据。资助:国家卫生和保健研究所。
{"title":"Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.","authors":"Seran Hakki, Jie Zhou, Jakob Jonnerby, Anika Singanayagam, Jack L Barnett, Kieran J Madon, Aleksandra Koycheva, Christine Kelly, Hamish Houston, Sean Nevin, Joe Fenn, Rhia Kundu, Michael A Crone, Timesh D Pillay, Shazaad Ahmad, Nieves Derqui-Fernandez, Emily Conibear, Paul S Freemont, Graham P Taylor, Neil Ferguson, Maria Zambon, Wendy S Barclay, Jake Dunning, Ajit Lalvani","doi":"10.1016/S2213-2600(22)00226-0","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00226-0","url":null,"abstract":"<p><strong>Background: </strong>Knowledge of the window of SARS-CoV-2 infectiousness is crucial in developing policies to curb transmission. Mathematical modelling based on scarce empirical evidence and key assumptions has driven isolation and testing policy, but real-world data are needed. We aimed to characterise infectiousness across the full course of infection in a real-world community setting.</p><p><strong>Methods: </strong>The Assessment of Transmission and Contagiousness of COVID-19 in Contacts (ATACCC) study was a UK prospective, longitudinal, community cohort of contacts of newly diagnosed, PCR-confirmed SARS-CoV-2 index cases. Household and non-household exposed contacts aged 5 years or older were eligible for recruitment if they could provide informed consent and agree to self-swabbing of the upper respiratory tract. The primary objective was to define the window of SARS-CoV-2 infectiousness and its temporal correlation with symptom onset. We quantified viral RNA load by RT-PCR and infectious viral shedding by enumerating cultivable virus daily across the course of infection. Participants completed a daily diary to track the emergence of symptoms. Outcomes were assessed with empirical data and a phenomenological Bayesian hierarchical model.</p><p><strong>Findings: </strong>Between Sept 13, 2020, and March 31, 2021, we enrolled 393 contacts from 327 households (the SARS-CoV-2 pre-alpha and alpha variant waves); and between May 24, 2021, and Oct 28, 2021, we enrolled 345 contacts from 215 households (the delta variant wave). 173 of these 738 contacts were PCR positive for more than one timepoint, 57 of which were at the start of infection and comprised the final study population. The onset and end of infectious viral shedding were captured in 42 cases and the median duration of infectiousness was 5 (IQR 3-7) days. Although 24 (63%) of 38 cases had PCR-detectable virus before symptom onset, only seven (20%) of 35 shed infectious virus presymptomatically. Symptom onset was a median of 3 days before both peak viral RNA and peak infectious viral load (viral RNA IQR 3-5 days, n=38; plaque-forming units IQR 3-6 days, n=35). Notably, 22 (65%) of 34 cases and eight (24%) of 34 cases continued to shed infectious virus 5 days and 7 days post-symptom onset, respectively (survival probabilities 67% and 35%). Correlation of lateral flow device (LFD) results with infectious viral shedding was poor during the viral growth phase (sensitivity 67% [95% CI 59-75]), but high during the decline phase (92% [86-96]). Infectious virus kinetic modelling suggested that the initial rate of viral replication determines the course of infection and infectiousness.</p><p><strong>Interpretation: </strong>Less than a quarter of COVID-19 cases shed infectious virus before symptom onset; under a crude 5-day self-isolation period from symptom onset, two-thirds of cases released into the community would still be infectious, but with reduced infectious viral shedding. Our ","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"1061-1073"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40627182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01Epub Date: 2022-09-26DOI: 10.1016/S2213-2600(22)00248-X
Carol L Hodgson, Alisa M Higgins, Michael J Bailey, Shannah Anderson, Stephen Bernard, Bentley J Fulcher, Denise Koe, Natalie J Linke, Jasmin V Board, Daniel Brodie, Heidi Buhr, Aidan J C Burrell, D James Cooper, Eddy Fan, John F Fraser, David J Gattas, Ingrid K Hopper, Sue Huckson, Edward Litton, Shay P McGuinness, Priya Nair, Neil Orford, Rachael L Parke, Vincent A Pellegrino, David V Pilcher, Jayne Sheldrake, Benjamin A J Reddi, Dion Stub, Tony V Trapani, Andrew A Udy, Ary Serpa Neto
Background: Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment.
Methods: This prospective, multicentre, registry-embedded cohort study was done at 23 hospitals in Australia from Feb 15, 2019, to Dec 31, 2020. The EXCEL registry included all adults (≥18 years) in Australia who were admitted to an intensive care unit (ICU) in a participating centre at the time of the study and who underwent ECMO. All patients who received ECMO support for respiratory failure, cardiac failure, or cardiac arrest during their ICU stay were eligible for this study. The primary outcome was death or moderate-to-severe disability (defined using the WHO Disability Assessment Schedule 2.0, 12-item survey) at 6 months after ECMO initiation. We used Fisher's exact test to compare categorical variables. This study is registered with ClinicalTrials.gov, NCT03793257.
Findings: Outcome data were available for 391 (88%) of 442 enrolled patients. The primary outcome of death or moderate-to-severe disability at 6 months was reported in 260 (66%) of 391 patients: 136 (67%) of 202 who received veno-arterial (VA)-ECMO, 60 (54%) of 111 who received veno-venous (VV)-ECMO, and 64 (82%) of 78 who received extracorporeal cardiopulmonary resuscitation (eCPR). After adjustment for age, comorbidities, Acute Physiology and Chronic Health Evaluation (APACHE) IV score, days between ICU admission and ECMO start, and use of vasopressors before ECMO, death or moderate-to-severe disability was higher in patients who received eCPR than in those who received VV-ECMO (VV-ECMO vs eCPR: risk difference [RD] -32% [95% CI -49 to -15]; p<0·001) but not VA-ECMO (VA-ECMO vs eCPR -8% [-22 to 6]; p=0·27).
Interpretation: In our study, only a third of patients were alive without moderate-to-severe disability at 6 months after initiation of ECMO. The finding that disability was common across all areas of functioning points to the need for long-term, multidisciplinary care and support for surviving patients who have had ECMO. Further studies are needed to understand the 180-day and longer-term prognosis of patients with different diagnoses receiving different modes of ECMO, which could have important implications for the selection of patients for ECMO and management strategies in the ICU.
Funding: The National Health and Medical Research Council of Australia.
背景:体外膜氧合(ECMO)是一种侵入性手术，用于短期内支持最严重形式的心脏或呼吸衰竭危重患者，但对死亡和残疾发生率的长期影响尚不清楚。我们的目的是评估治疗后6个月(180天)ECMO相关的死亡或残疾发生率。方法:这项前瞻性、多中心、登记嵌入队列研究于2019年2月15日至2020年12月31日在澳大利亚的23家医院进行。EXCEL登记包括澳大利亚所有在研究时入住参与中心重症监护病房(ICU)并接受ECMO的成年人(≥18岁)。所有在ICU住院期间因呼吸衰竭、心力衰竭或心脏骤停而接受ECMO支持的患者均符合本研究的条件。主要结局为ECMO开始后6个月死亡或中度至重度残疾(使用WHO残疾评估表2.0,12项调查定义)。我们使用费雪精确检验来比较分类变量。本研究已在ClinicalTrials.gov注册，编号NCT03793257。结果:442例入组患者中有391例(88%)可获得结局数据。391例患者中有260例(66%)报告了6个月死亡或中度至重度残疾的主要结局:202例接受静脉-动脉(VA)-ECMO的患者中有136例(67%)，111例接受静脉-静脉(VV)-ECMO的患者中有60例(54%)，78例接受体外心肺复苏(eCPR)的患者中有64例(82%)。在调整了年龄、合共病、急性生理和慢性健康评估(APACHE) IV评分、从ICU入院到ECMO开始的天数以及ECMO前血管加压药物的使用情况后，接受eCPR的患者的死亡率或中度至重度残疾高于接受VV-ECMO的患者(VV-ECMO vs eCPR:风险差异[RD] -32% [95% CI -49 ~ -15];VA-ECMO vs eCPR -8%[-22至6];p = 0·27)。解释:在我们的研究中，只有三分之一的患者在ECMO开始后6个月没有中度至重度残疾。研究发现，残疾在所有功能点都很常见，需要长期的、多学科的护理和支持存活的ECMO患者。不同诊断的患者接受不同模式ECMO的180天及更长期预后情况有待进一步研究，这对选择ECMO患者及ICU管理策略具有重要意义。资助:澳大利亚国家卫生和医学研究委员会。
{"title":"Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study.","authors":"Carol L Hodgson, Alisa M Higgins, Michael J Bailey, Shannah Anderson, Stephen Bernard, Bentley J Fulcher, Denise Koe, Natalie J Linke, Jasmin V Board, Daniel Brodie, Heidi Buhr, Aidan J C Burrell, D James Cooper, Eddy Fan, John F Fraser, David J Gattas, Ingrid K Hopper, Sue Huckson, Edward Litton, Shay P McGuinness, Priya Nair, Neil Orford, Rachael L Parke, Vincent A Pellegrino, David V Pilcher, Jayne Sheldrake, Benjamin A J Reddi, Dion Stub, Tony V Trapani, Andrew A Udy, Ary Serpa Neto","doi":"10.1016/S2213-2600(22)00248-X","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00248-X","url":null,"abstract":"<p><strong>Background: </strong>Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment.</p><p><strong>Methods: </strong>This prospective, multicentre, registry-embedded cohort study was done at 23 hospitals in Australia from Feb 15, 2019, to Dec 31, 2020. The EXCEL registry included all adults (≥18 years) in Australia who were admitted to an intensive care unit (ICU) in a participating centre at the time of the study and who underwent ECMO. All patients who received ECMO support for respiratory failure, cardiac failure, or cardiac arrest during their ICU stay were eligible for this study. The primary outcome was death or moderate-to-severe disability (defined using the WHO Disability Assessment Schedule 2.0, 12-item survey) at 6 months after ECMO initiation. We used Fisher's exact test to compare categorical variables. This study is registered with ClinicalTrials.gov, NCT03793257.</p><p><strong>Findings: </strong>Outcome data were available for 391 (88%) of 442 enrolled patients. The primary outcome of death or moderate-to-severe disability at 6 months was reported in 260 (66%) of 391 patients: 136 (67%) of 202 who received veno-arterial (VA)-ECMO, 60 (54%) of 111 who received veno-venous (VV)-ECMO, and 64 (82%) of 78 who received extracorporeal cardiopulmonary resuscitation (eCPR). After adjustment for age, comorbidities, Acute Physiology and Chronic Health Evaluation (APACHE) IV score, days between ICU admission and ECMO start, and use of vasopressors before ECMO, death or moderate-to-severe disability was higher in patients who received eCPR than in those who received VV-ECMO (VV-ECMO vs eCPR: risk difference [RD] -32% [95% CI -49 to -15]; p<0·001) but not VA-ECMO (VA-ECMO vs eCPR -8% [-22 to 6]; p=0·27).</p><p><strong>Interpretation: </strong>In our study, only a third of patients were alive without moderate-to-severe disability at 6 months after initiation of ECMO. The finding that disability was common across all areas of functioning points to the need for long-term, multidisciplinary care and support for surviving patients who have had ECMO. Further studies are needed to understand the 180-day and longer-term prognosis of patients with different diagnoses receiving different modes of ECMO, which could have important implications for the selection of patients for ECMO and management strategies in the ICU.</p><p><strong>Funding: </strong>The National Health and Medical Research Council of Australia.</p>","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"1038-1048"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40382751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01Epub Date: 2022-09-30DOI: 10.1016/S2213-2600(22)00396-4
Priya Venkatesan
{"title":"European Respiratory Society International Congress 2022.","authors":"Priya Venkatesan","doi":"10.1016/S2213-2600(22)00396-4","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00396-4","url":null,"abstract":"","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"e103-e104"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40395500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1016/S2213-2600(22)00355-1
Amy Attaway, Philippe Haouzi
{"title":"When should we treat moderate hypoxaemia in patients with COPD?","authors":"Amy Attaway, Philippe Haouzi","doi":"10.1016/S2213-2600(22)00355-1","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00355-1","url":null,"abstract":"","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"e97"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40665040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01Epub Date: 2022-07-08DOI: 10.1016/S2213-2600(22)00225-9
Wolfram Windisch, Friederike Sophie Magnet
{"title":"Long-term oxygen therapy in COPD: what is the evidence?","authors":"Wolfram Windisch, Friederike Sophie Magnet","doi":"10.1016/S2213-2600(22)00225-9","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00225-9","url":null,"abstract":"","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"1010-1011"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40493634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01Epub Date: 2022-09-23DOI: 10.1016/S2213-2600(22)00302-2
Alvar Agusti, Claus F Vogelmeier, David M G Halpin
{"title":"Tackling the global burden of lung disease through prevention and early diagnosis.","authors":"Alvar Agusti, Claus F Vogelmeier, David M G Halpin","doi":"10.1016/S2213-2600(22)00302-2","DOIUrl":"https://doi.org/10.1016/S2213-2600(22)00302-2","url":null,"abstract":"","PeriodicalId":326030,"journal":{"name":"The Lancet. Respiratory medicine","volume":" ","pages":"1013-1015"},"PeriodicalIF":76.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40375443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：